Tashiro Hideya, Sagawa Teiri, Okada Kenzoh, Kurokawa Tatsuo, Soga Hiroyuki, Watanabe Ryohei, Yasuoka Yasuo, Honda Kazuo, Watanabe Yuji, Gangi Junichi, Akehi Shun, Masuda Jun, Nomoto Masahiro
Dept. of Surgery, Oita Prefectural Hospital.
Gan To Kagaku Ryoho. 2007 Mar;34(3):393-6.
The safety of docetaxel (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) every three weeks (TC) as adjuvant therapy for Japanese women with operable breast cancer was evaluated. Ehime TC Study Group initiated the randomized control study,which compared the effects of the TC course number (4 cycles versus 8 cycles) in the adjuvant setting on the treatment outcomes of breast cancer patients. Eight patients were investigated on the side effects of TC therapy, four of them were allocated to 4 cycles of TC, and four to eight cycles from May, 2004 to Feb. 2005. Leukocytopenia and neutropenia of grade 3 or 4 were seen in 50% and 63% of the cases, respectively. No febrile neutropenia was seen. Although the non-hematological side effects of grade 3 or 4 were not observed, alopecia, stomatitis, skin toxicities and edema of grade 2 were seen in 100%, 25%, 25%, 13% of cases, respectively. TC therapy was well tolerated. All anticancer drugs could be administered as scheduled. From these preliminary results, TC therapy seems to be able to be safely prescribed postoperatively for Japanese women operated for breast cancer.
对多西他赛（60mg/m²）联合环磷酰胺（600mg/m²）每三周一次（TC方案）作为日本可手术乳腺癌女性辅助治疗的安全性进行了评估。爱媛TC研究组开展了一项随机对照研究，比较了辅助治疗中TC疗程数（4个周期与8个周期）对乳腺癌患者治疗结局的影响。2004年5月至2005年2月，对8例患者进行了TC治疗副作用的调查，其中4例接受4个周期的TC治疗，4例接受8个周期的TC治疗。3级或4级白细胞减少症和中性粒细胞减少症的发生率分别为50%和63%。未观察到发热性中性粒细胞减少症。虽然未观察到3级或4级非血液学副作用，但2级脱发、口腔炎、皮肤毒性和水肿的发生率分别为100%、25%、25%、13%。TC治疗耐受性良好。所有抗癌药物均能按计划给药。从这些初步结果来看，TC治疗似乎可以安全地用于日本接受乳腺癌手术的女性术后治疗。
